Discovery of potential HER2 inhibitors from Mangifera indica for the treatment of HER2-Positive breast cancer: an integrated computational approach
- 13 September 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 40 (23) , 12772-12784
Abstract
Human epidermal growth factor receptor 2 (HER2) is a member of epidermal growth factor receptors with tyrosine kinase functionality. The dimerization of HER2 leads to the autophosphorylation of tyrosine residues within its cytoplasmic domain, resulting in hyperactivation of several downstream signal transduction pathways that play an important role in tumorigenesis, cancer aggressiveness and cell proliferation. Amplification or overexpression of HER2 has been found in approximately 15–30% of breast cancers. Hence, HER2 serve as a therapeutic biomarker in breast cancer. Herein, we applied structural bioinformatics techniques via molecular docking, molecular dynamics simulations, Molecular mechanics/generalized Born surface area (MM/GBSA) calculations and pharmacokinetic models to identify putative HER2 inhibitors. Application of stringent molecular docking results in the identification of bioactive compounds from Mangifera indica as selective, potent inhibitors of HER2. However, only the top three compounds with the highest negative docking score (< −9kcal/mol) was considered in reference to neratinib (−8.601 kcal/mol) for computational analysis. The molecular dynamics simulations and post-simulation analysis of docked HER2-ligand complexes unveil the substantial stability for M. indica ligands over the 100 ns simulation period. Additionally, MM/GBSA binding free energy calculation supports the inhibitory potential for the docked ligands, which exclusively revealed the highest binding energy for selected M. indica ligands than the reference compound (neratinib). The pharmacokinetic model showed that M. indica ligands are promising therapeutic agents. Conclusively, bioactive compounds from M. indica may serve as lead molecules that could be developed into potent and effective HER2 inhibitors for breast cancer treatment. Communicated by Ramaswamy H. SarmaKeywords
Funding Information
- None
This publication has 56 references indexed in Scilit:
- admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET PropertiesJournal of Chemical Information and Modeling, 2012
- Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patientsBritish Journal of Cancer, 2012
- Beyond trastuzumab: New treatment options for HER2-positive breast cancerThe Breast, 2011
- Rutin inhibits human leukemia tumor growth in a murine xenograft model in vivoEnvironmental Toxicology, 2011
- The role of HER2 in cancer therapy and targeted drug deliveryJournal of Controlled Release, 2010
- Identification and Quantification of Xanthophyll Esters, Carotenes, and Tocopherols in the Fruit of Seven Mexican Mango Cultivars by Liquid Chromatography−Atmospheric Pressure Chemical Ionization−Time-of-Flight Mass Spectrometry [LC-(APcI+)-MS]Journal of Agricultural and Food Chemistry, 2007
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Natural Products as Sources of New Drugs over the Period 1981−2002Journal of Natural Products, 2003
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003